
    
      This study enrolls participants with high risk NMIBC and FGFR mutations or fusions.
      Erdafitinib is an oral pan-fibroblast growth factor receptor (FGFR) 1-4 inhibitor with
      demonstrated clinical activity in participants with solid tumors, including urothelial
      carcinoma, with alterations in the FGFR pathway. In Cohort 1, participants will be randomized
      to erdafitinib or to Investigators Choice (intravesical gemcitabine or intravesical
      MMC/hyperthermic MMC). The study consists of Screening period, Treatment Phase and Follow-up
      Phase.
    
  